Our Approach to Corporate Responsibility
At Ionis, we work with a sense of urgency to discover, develop and deliver medicines to create a better future for people with serious diseases. We believe operating responsibly and sustainably creates long-term value for our company and our stakeholders.
As our business grows, Ionis continues to reinforce our commitment to corporate responsibility in all aspects of our work. Our three corporate responsibility strategic pillars and associated goals guide our approach and provide a framework for reporting on our performance.
To learn more about our corporate responsibility priorities, download our Materiality Assessment.
Corporate Responsibility Report
To learn more about our corporate responsibility priorities, download our Corporate Responsibility Report.
Corporate Responsibility Strategic Pillars
We innovate across the business and work tirelessly to discover, develop and deliver important new medicines for people with serious diseases.
Goals
- Maintain strong investment in innovative R&D rooted in the needs of people with serious disease
- Collaborate with organizations that address important needs in patient communities
- Ensure high-quality processes to support clinical development and safe, reliable product supply
- Support equitable access and affordability of our medicines
We are committed to fostering an inclusive culture that drives excellence, embraces diversity and supports our communities.
Goals
- Cultivate a thriving workplace culture that is safe, inclusive and fosters innovation
- Continue to strengthen and expand diversity, equity and inclusion across the company
- Drive positive social impact through employee volunteerism and community support
We operate with integrity to help create a better, more sustainable future for all through environmental stewardship and responsible business practices and stakeholder interactions.
Goals
- Act with integrity and uphold our commitment to high ethical standards
- Responsibly manage our environmental impact as we grow our operations
Our 2025 Corporate Responsibility Report
Our 2025 Corporate Responsibility Report: Building Momentum for Better Futures is our fifth annual report and details our ongoing commitment to corporate responsibility and transparency through enhanced disclosures. This report outlines our progress across our three CR pillars and associated goals that we introduced in 2023.
Report highlights include:
- Celebrated the U.S. approval of DAWNZERA™, the first and only RNA-targeted medicine approved for hereditary angioedema (HAE), and the successful commercial launch of TRYNGOLZA® for people living with familial chylomicronemia syndrome (FCS) as an adjunct to diet, our first two independent medicines
- Announced potentially transformative positive Phase 3 results for our investigational medicines for severe hypertriglyceridemia (sHTG) and Alexander’s disease (AxD)
- Expanded Ionis Every Step™ program to include both of our approved medicines, TRYNGOLZA and DAWNZERA
- Partnered with more than 100 patient and caregiver advocacy groups in the U.S. and globally
- Ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
- Gave back to our local communities through 2,100+ hours of employee volunteering and $5.5M in corporate contributions
- Completed first Climate Risk Assessment to enhance resilience and disclosure in our TCFD Report
- Continued to sustainably manage our environmental impact as our business grows
- Further evolved our policies, resources and training for patient and HCP interactions and salesforce engagement
